BACKGROUND
- Psoriasis is a chronic inflammatory disorder affecting the skin, scalp, and nails.
- Up to 80% of patients with psoriasis have nail involvement.
- Nail psoriasis is persistent, slow to resolve, difficult to treat, and can impair daily activities.
- IXORA-S is a Phase 3b, multicenter trial that compared the efficacy of ixekizumab with ustekinumab in patients with moderate-to-severe psoriasis.

RESULTS
- Significantly more ixekizumab-treated patients achieved PASI 90 and PASI 100 versus ustekinumab from Week 4 through Week 52 (Primary Endpoint).

METHODS
- Study Design: IXORA-S
- Baseline Patient Demographics and Characteristics, ITT Population With Baseline Fingernail Psoriasis

CONCLUSIONS
- Improvement in nail psoriasis lesions was observed in both treatment groups in IXORA-S.
- Complete resolution of nail psoriasis was seen in significantly greater percentages of patients treated with ixekizumab compared with ustekinumab from Week 16 through Week 52 of treatment.
- Results suggest that ixekizumab provides significantly greater clearance of nail psoriasis than ustekinumab.
- Longer periods of observation will be required to determine if lesions continue to improve beyond 52 weeks of treatment.

Disclosures
- N. Wasel has provided consultancy services for: Abbott Laboratories, Amgen, Astellas Pharma, Biogen Idec, EMD Serono, Isotechnika, Janssen-Ortho, Ortho Biotech, Schering-Plough, and Wyeth.
- Y. Dutronc has performed contract research for: Abbott Laboratories, Amgen, Astellas Pharma, Biogen Idec, EMD Serono, Isotechnika, Leo Pharma, Merck Frosst, Novartis Pharmaceuticals, Pfizer, Takeda, and Wyeth.
- B. Schinzel has been a current employee and stockholder of Eli Lilly and Company.
- C. Lacour has been a consultant for: AbbVie, Boehringer, Celgene, Eli Lilly and Company, Janssen-Ortho, Merck & Co, and Novartis.
- L. Bergrenn of Clinipace Worldwide provided statistical support for this presentation.
- This study was sponsored by Eli Lilly and Company.
- Medical writing services were provided by Samantha Forster, PhD, of Presticore—a part of Envision Pharma Group, and were funded by Eli Lilly and Company.

References
- Ghislanzoni P-D, et al. EADV 26th Congress. 2017;P1868.